

Oryzon to present at upcoming international conferences

- ❖ **Rodman & Renshaw 20th Annual Global Investment Conference, New York, USA**
- ❖ **19th International Conference on Alzheimer's Drug Discovery, Jersey City, NJ, USA**
- ❖ **BIO-SPAIN-2018, Sevilla, SPAIN**
- ❖ **European Molecular Biology Laboratory (EMBL) Corporate Summer School, Heidelberg, GERMANY**

MADRID, SPAIN and CAMBRIDGE, MA, September 3rd, 2018 - Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that Executive Directors of the company will present at several international reputed conferences in September.

Dr. Carlos Buesa, Oryzon's CEO, will participate at the Rodman & Renshaw 20th Annual Global Investment Conference that will take place at the St. Regis Hotel in New York, on September 4-6. The presentation of the company will be on September 6th at the "Library" room at 3:00 pm US ET.

Dr. Roger Bullock, CMO, and Dr. Tamara Maes, CSO, will attend the 19th International Conference on Alzheimer's Drug Discovery, to be held at the Hyatt Regency Hotel, 2 Exchange Place in Jersey City, NJ, USA on September 16-17

Dr. Maes will also attend the European Molecular Biology Laboratory (EMBL) Corporate Summer School in Heidelberg, Germany that takes place from September 16th till 22nd. Dr. Maes will deliver a presentation entitled "LSD1 inhibitors: the journey from target identification to clinical trials" on September 20th.

Finally, the company will participate with a corporate pavilion at the BIO-SPAIN-2018 fair, the conference and partnering event organized every two years by ASEBIO, the Spanish Association of Bioindustries. Bio-Spain will be held in Seville on September 25-27. Oryzon's CMO Dr. Roger Bullock will moderate a panel of dementia experts (see <https://biospain2018.org/program/#event-65>) while Oryzon's CSO Dr. Tamara Maes will participate in the Precision Medicine panel (see <https://biospain2018.org/program/#event-162>), both on September 25. In addition, the CEO of the company Dr. Carlos Buesa will moderate a financing and stock exchange panel on September 26 (see <https://biospain2018.org/program/#event-144>).

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field. Oryzon's LSD1 program has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. The company has offices in Spain and USA. For more information, visit www.oryzon.com.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the *Comisión Nacional del Mercado de Valores*, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A. have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States. The Company's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company's securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

US Contact:

The Trout Group
Thomas Hoffmann
+1 646 378 2932
thoffmann@troutgroup.com

Spain:

ATREVIA
Patricia Cobo/Luis Rejano
+34 91 564 07 25
pcobo@atrevia.com
lrejano@atrevia.com

The Company:

Emili Torrell
BD Director
+34 93 515 13 13
etorrell@oryzon.com